DK170005B1 - In vitro diagnostisk fremgangsmåde og sæt eller system til detektering af forekomst af kræftceller eller andre mucinantigenproducerende celler hos en patient - Google Patents
In vitro diagnostisk fremgangsmåde og sæt eller system til detektering af forekomst af kræftceller eller andre mucinantigenproducerende celler hos en patient Download PDFInfo
- Publication number
- DK170005B1 DK170005B1 DK088086A DK88086A DK170005B1 DK 170005 B1 DK170005 B1 DK 170005B1 DK 088086 A DK088086 A DK 088086A DK 88086 A DK88086 A DK 88086A DK 170005 B1 DK170005 B1 DK 170005B1
- Authority
- DK
- Denmark
- Prior art keywords
- lima
- antibodies
- sima
- fragments
- sample
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 57
- 102000036639 antigens Human genes 0.000 title claims abstract description 57
- 108091007433 antigens Proteins 0.000 title claims abstract description 57
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 43
- 201000011510 cancer Diseases 0.000 title claims abstract description 30
- 238000000338 in vitro Methods 0.000 title claims abstract description 11
- 238000002405 diagnostic procedure Methods 0.000 title claims abstract description 8
- 238000009007 Diagnostic Kit Methods 0.000 title claims abstract description 6
- 108010063954 Mucins Proteins 0.000 claims abstract description 53
- 102000015728 Mucins Human genes 0.000 claims abstract description 53
- 210000002966 serum Anatomy 0.000 claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 23
- 210000004369 blood Anatomy 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 16
- 239000012530 fluid Substances 0.000 claims abstract description 11
- 210000002381 plasma Anatomy 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 210000001072 colon Anatomy 0.000 claims description 17
- 238000002372 labelling Methods 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 12
- 108010034592 gastro-intestinal mucus-associated antigens Proteins 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 4
- 230000008105 immune reaction Effects 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 8
- 210000000813 small intestine Anatomy 0.000 abstract description 7
- 210000002429 large intestine Anatomy 0.000 abstract description 2
- 206010009944 Colon cancer Diseases 0.000 description 27
- 230000000890 antigenic effect Effects 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 26
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 21
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 238000003018 immunoassay Methods 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 238000011282 treatment Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 208000029742 colonic neoplasm Diseases 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 9
- 230000002860 competitive effect Effects 0.000 description 9
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 229920000136 polysorbate Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 150000002402 hexoses Chemical class 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 108090000526 Papain Proteins 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 229940055729 papain Drugs 0.000 description 5
- 235000019834 papain Nutrition 0.000 description 5
- 229940111202 pepsin Drugs 0.000 description 5
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 229940051875 mucins Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 108090001092 clostripain Proteins 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101100365800 Drosophila melanogaster sima gene Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 101000941450 Lasioglossum laticeps Lasioglossin-1 Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241001526457 Limaria Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analyzing Materials By The Use Of Fluid Adsorption Or Reactions (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPG567284 | 1984-06-25 | ||
| AUPG567284 | 1984-06-25 | ||
| PCT/AU1985/000136 WO1986000414A1 (en) | 1984-06-25 | 1985-06-21 | In vitro detection of gastrointestinal cancer |
| AU8500136 | 1985-06-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK88086A DK88086A (da) | 1986-02-25 |
| DK88086D0 DK88086D0 (da) | 1986-02-25 |
| DK170005B1 true DK170005B1 (da) | 1995-04-24 |
Family
ID=3770652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK088086A DK170005B1 (da) | 1984-06-25 | 1986-02-25 | In vitro diagnostisk fremgangsmåde og sæt eller system til detektering af forekomst af kræftceller eller andre mucinantigenproducerende celler hos en patient |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US4818682A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0190159B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2520107B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR920010296B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1034976C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE80470T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU596075B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA1263598A (cg-RX-API-DMAC7.html) |
| DK (1) | DK170005B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES8703023A1 (cg-RX-API-DMAC7.html) |
| GR (1) | GR851540B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ212419A (cg-RX-API-DMAC7.html) |
| PH (1) | PH23387A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1986000414A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA854700B (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5160723A (en) * | 1985-04-19 | 1992-11-03 | Sloan-Kettering Institute For Cancer Research | Method of imaging colorectal carcinoma lesion and composition for use therein |
| ES8800604A1 (es) * | 1985-04-22 | 1987-11-16 | Hybritech Inc | Un metodo para producir anticuerpos monoclonales |
| US5552291A (en) * | 1985-10-09 | 1996-09-03 | Kyowa, Hakko Kogyo Co., Ltd. | Anti-human pulmonary adenocarcinoma specific monoclonal antibody |
| JPH0673470B2 (ja) * | 1986-07-15 | 1994-09-21 | 協和醗酵工業株式会社 | 抗ヒト胃癌単クロ−ン性抗体ａｍｃ−４６２ |
| JP2519038B2 (ja) * | 1986-07-29 | 1996-07-31 | 郁男 山科 | 単クロ―ン抗体及びその製造方法 |
| AU613590B2 (en) * | 1986-11-19 | 1991-08-08 | Bristol-Myers Squibb Company | Hybridomas producing monoclonal antibodies to new mucin epitopes |
| US6004761A (en) * | 1986-11-19 | 1999-12-21 | Sanofi | Method for detecting cancer using monoclonal antibodies to new mucin epitopes |
| JP2688824B2 (ja) * | 1987-05-29 | 1997-12-10 | 郁男 山科 | 単クローン抗体ｎｋｙ１３ |
| US5073493A (en) * | 1987-05-29 | 1991-12-17 | Ikuo Yamashina | Monoclonal antibody nky13 |
| US5075218A (en) * | 1987-12-29 | 1991-12-24 | Biomira, Inc. | Screening for antibodies which bind carbohydrate epitopes of tumor-associated antigens, and uses thereof |
| US4921789A (en) * | 1988-04-20 | 1990-05-01 | New England Deaconess Hospital Corporation | Marker for colorectal carcinoma and methods of detecting the same |
| US5292667A (en) * | 1988-06-29 | 1994-03-08 | The General Hospital Corporation | Detection and treatment of ulcerative colitis |
| WO1990012892A1 (en) * | 1989-04-14 | 1990-11-01 | The Regents Of The University Of California | Human intestinal mucin |
| ATE145727T1 (de) * | 1989-09-15 | 1996-12-15 | Genetic Systems Corp | Hybridoma ct43, das ein antikörper gegen ein mucinepitop von darmkrebs erzeugt |
| US5242799A (en) * | 1989-11-02 | 1993-09-07 | Biomira, Inc. | Lectin-antibody immunoassays for TF epitope-bearing antigens |
| US5110911A (en) * | 1989-11-02 | 1992-05-05 | Biomira, Inc. | Human tumor-associated thomsen-friedenreich antigen |
| WO1991008217A1 (en) * | 1989-12-05 | 1991-06-13 | The Regents Of The University Of California | Human intestinal mucins |
| US5256540A (en) * | 1990-12-28 | 1993-10-26 | Mayo Foundation For Medical Education And Research | Immunoassay for small cell lung carcinoma |
| US5281697A (en) * | 1991-05-31 | 1994-01-25 | Applied Biotechnology, Inc. | CEA-binding protein and uses thereof |
| US5278290A (en) * | 1991-05-31 | 1994-01-11 | Applied Biotechnology, Inc. | Binding protein for CEA and uses thereof |
| US5245017A (en) * | 1991-05-31 | 1993-09-14 | Applied Biotechnology, Inc. | Method for isolating CEA-binding protein |
| EP0556496A3 (en) * | 1992-02-21 | 1993-12-29 | Dev Ct Biotechnology | Antibodies against tumor-associated mucin glycoprotein |
| AU1257895A (en) * | 1993-11-17 | 1995-06-06 | Schepens Eye Research Institute, Inc., The | Antibody to ocular and vaginal surface epithelium |
| US5416025A (en) * | 1993-11-29 | 1995-05-16 | Krepinsky; Jiri J. | Screening test for early detection of colorectal cancer |
| US5498608A (en) * | 1994-01-07 | 1996-03-12 | Salix Pharmaceuticals | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
| CA2253093A1 (en) | 1998-11-06 | 2000-05-06 | Jiri J. Krepinsky | Screening test for early detection of colorectal cancer |
| SE0004532D0 (sv) * | 2000-12-07 | 2000-12-07 | Caldwell Karin Dahlgren | Use of mucin |
| US7659240B2 (en) * | 2002-01-14 | 2010-02-09 | Vertex Pharmaceuticals Incorporated | Mucin immobilized chromatography |
| ITTO20121154A1 (it) * | 2012-12-27 | 2014-06-28 | Fond Istituto Italiano Di Tecnologia | Sistema di sonde per rivelare una sequenza nucleotidica bersaglio a singolo filamento |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4277437A (en) * | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| CA1274794A (en) * | 1983-01-21 | 1990-10-02 | Frederick James Primus | Specific cea-family antigens, antibodies specific thereto and their methods of use |
| US4579827A (en) * | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
-
1985
- 1985-06-14 NZ NZ212419A patent/NZ212419A/xx unknown
- 1985-06-21 AU AU44996/85A patent/AU596075B2/en not_active Expired
- 1985-06-21 KR KR1019860700115A patent/KR920010296B1/ko not_active Expired
- 1985-06-21 ZA ZA854700A patent/ZA854700B/xx unknown
- 1985-06-21 JP JP60502755A patent/JP2520107B2/ja not_active Expired - Fee Related
- 1985-06-21 AT AT85902944T patent/ATE80470T1/de not_active IP Right Cessation
- 1985-06-21 WO PCT/AU1985/000136 patent/WO1986000414A1/en not_active Ceased
- 1985-06-21 EP EP85902944A patent/EP0190159B1/en not_active Expired - Lifetime
- 1985-06-21 US US06/860,223 patent/US4818682A/en not_active Expired - Lifetime
- 1985-06-24 ES ES85544483A patent/ES8703023A1/es not_active Expired
- 1985-06-24 CA CA000484996A patent/CA1263598A/en not_active Expired
- 1985-06-24 GR GR851540A patent/GR851540B/el unknown
- 1985-06-24 PH PH32443A patent/PH23387A/en unknown
- 1985-07-16 CN CN85105430A patent/CN1034976C/zh not_active Expired - Lifetime
-
1986
- 1986-02-25 DK DK088086A patent/DK170005B1/da not_active IP Right Cessation
-
1988
- 1988-11-14 US US07/270,765 patent/US5008184A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1034976C (zh) | 1997-05-21 |
| KR860700154A (ko) | 1986-03-31 |
| AU596075B2 (en) | 1990-04-26 |
| CN85105430A (zh) | 1987-05-13 |
| JP2520107B2 (ja) | 1996-07-31 |
| US5008184A (en) | 1991-04-16 |
| EP0190159A4 (en) | 1988-08-04 |
| KR920010296B1 (ko) | 1992-11-21 |
| ZA854700B (en) | 1986-02-26 |
| ES544483A0 (es) | 1987-01-16 |
| EP0190159A1 (en) | 1986-08-13 |
| DK88086A (da) | 1986-02-25 |
| NZ212419A (en) | 1988-08-30 |
| GR851540B (cg-RX-API-DMAC7.html) | 1985-11-25 |
| ATE80470T1 (de) | 1992-09-15 |
| DK88086D0 (da) | 1986-02-25 |
| CA1263598A (en) | 1989-12-05 |
| ES8703023A1 (es) | 1987-01-16 |
| AU4499685A (en) | 1986-01-24 |
| EP0190159B1 (en) | 1992-09-09 |
| JPS61502701A (ja) | 1986-11-20 |
| PH23387A (en) | 1989-07-26 |
| WO1986000414A1 (en) | 1986-01-16 |
| US4818682A (en) | 1989-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK170005B1 (da) | In vitro diagnostisk fremgangsmåde og sæt eller system til detektering af forekomst af kræftceller eller andre mucinantigenproducerende celler hos en patient | |
| Munthe et al. | Characterization of IgG complexes in eluates from rheumatoid tissue | |
| US4544640A (en) | Anti immune complex antibody for determining SLE, rheumatoid arthritis or tetanus | |
| EP0678744B1 (en) | Method for detecting urinary tumor associated antigens | |
| Rahman et al. | A monoclonal antibody specific for the Thomsen-Friedenreich cryptic T antigen. | |
| PL177771B1 (pl) | Linie komórek hybrydoma i preparaty przeciwciał | |
| JP2959837B2 (ja) | 癌関連ハプトグロビン | |
| EP0200464B1 (en) | A tumor associated antigen | |
| JPS61282096A (ja) | 新規な腫瘍関連抗原 | |
| JPS62501563A (ja) | リウマチ性関節炎の特徴である蛋白質 | |
| JP3137976B2 (ja) | 結腸癌のムチンエピトープに対するモノクローナル抗体を産生するハイブリドーマｃｔ４３ | |
| JPS60500427A (ja) | 特異性ｃｅａファミリ−抗原、それに対し特異性の抗体およびそれらの使用方法 | |
| EP0226443B1 (en) | Human conglutinin | |
| Dolcher et al. | Autoantibodies from mixed cryoglobulinaemia patients bind glomerular antigens | |
| Vuento et al. | Isolation from human gastric juice of an antigen closely related to the carcinoembryonic antigen | |
| Ekramoddoullah et al. | Isolation of a Kentucky Blue Grass pollen allergen using a murine monoclonal antibody immunosorbent | |
| Michaelsen et al. | Sheep, rabbit and chicken antisera against a human VH fragment: reactivity with immunoglobulins and lymphocytes | |
| NO860676L (no) | Fremgangsm¨te og middel for in vitro p¨visning av cancer. | |
| Hill et al. | Immunoglobulins reactive to carcinoembryonic antigen and their relationship to the antigen in malignant ascitic fluid of ovarian carcinoma | |
| JPH08208698A (ja) | モノクローナル抗体 | |
| DE3586628T2 (de) | In vitro-nachweis von gastrointestinalem krebs. | |
| Tsuji et al. | Detection of the circulating lung cancer marker LCAP with a new monoclonal antibody TRD-L1 | |
| JPS61250000A (ja) | モノクロ−ナル抗体 | |
| WO2022018495A1 (en) | Immunoassay for detecting tumor pyruvate kinase m2 | |
| JPS63258495A (ja) | ポリペプチド組成物、その製法、それを用いる試験法、それを含む診断用キット及びそれに対する抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHB | Application shelved due to non-payment | ||
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |
Country of ref document: DK |